AMRX (AMRX) Stock Analysis
Verdict: HOLD
Robust specialty drug execution drives EPS inflection toward $1.01 in 2026, though a $2.43B net debt load caps valuation expansion.
Investment score: 62/100
Amneal Pharmaceuticals exhibits powerful earnings momentum and improving margins, but high leverage ($2.43B net debt) and proximity to its 52-week high make HOLD the optimal rating.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| TARS | -72.71 | 9.92 | 5.62 | -93.54 | — | -0.08 |
| MBX | -26.72 | 7.47 | 0.00 | -27.83 | — | 0.00 |
| GPCR | -11.70 | 1.90 | 0.00 | -8.36 | — | 0.00 |
| HRMY | 13.60 | 2.47 | 2.57 | 7.49 | — | 0.19 |
| SUPN | -22.35 | 2.42 | 3.00 | -148.25 | — | -0.13 |